Answer
The most commonly reported adverse reaction to TAKHZYRO (lanadelumab) is injection site reactions (52.4%), including pain, redness and bruising at the injection site.
Sources for this answer
- TAKHZYRO 300 mg solution for injection in pre-filled syringeTakeda UK Ltd · emc · SmPC §4.8 Undesirable effects · Version 8Document updated
Sources checked